ADAP - Adaptimmune Therapeutics plc
| Previous Close | 4.0000 |
| Open | 4.0300 |
| Bid | 0.0000 x 1400 |
| Ask | 4.4000 x 2200 |
| Day's Range | 4.0000 - 4.1300 |
| 52 Week Range | 0.7090 - 6.0000 |
| Volume | 804,139 |
| Avg. Volume | 1,881,204 |
| Market Cap | 427.772M |
| Beta (5Y Monthly) | 1.83 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3910 |
| Earnings Date | Nov 05, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.50 |
- American City Business Journals
Philadelphia cell therapy company prices $84M public stock offering
The company developing new cancer therapies is selling 21 million American depository shares at $4 each.
- GlobeNewswire
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
Adaptimmune Therapeutics plc (“Adaptimmune”)(ADAP), a leader in T-cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 21,000,000 of its American Depositary Shares (“ADSs”) at a price to the public of $4.00 per ADS. In connection with the offering, Adaptimmune has granted the underwriters a 30-day option to purchase up to an additional 3,150,000 ADSs at the public offering price. The gross offering size for this offering is expected to be approximately $84.0 million, excluding any exercise of the underwriters' option to purchase additional ADSs.
- Benzinga
The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 21) Abbott Laboratories (NYSE: ABT ) Apellis Pharmaceuticals ...
- Zacks
Top Ranked Momentum Stocks to Buy for January 22nd
Top Ranked Momentum Stocks to Buy for January 22nd
- GlobeNewswire
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
Adaptimmune Therapeutics plc (ADAP), a leader in T-cell therapy to treat cancer, today announced that it intends to offer and sell American Depositary Shares (“ADSs”) in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Adaptimmune also expects to grant the underwriters a 30-day option to purchase additional ADSs at the public offering price.
- Zacks
What Makes Adaptimmune Therapeutics PLC (ADAP) a New Buy Stock
Adaptimmune Therapeutics PLC (ADAP) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Benzinga
The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 14.) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ...
- TipRanks
After a Massive Gain, Is There Still Room for Adaptimmune (ADAP) Stock to Soar?
In a single day, the talk on the Street has zeroed in on one stock, oncology-focused cell therapy company Adaptimmune Therapeutics (ADAP). Following its presentation of promising data at the 38th annual J.P. Morgan Healthcare Conference, shares took off, posting a whopping 200% one-day gain.The data revealed that its MAGE-A4 (ADP-A2M4 and next-generation ADP-A2M4CD8) and AFP (ADP-A2AFP) therapies, part of its SPEAR T-cell platform, demonstrated initial solid tumor responses in four indications: gastro-esophageal junction, head and neck, liver cancers and melanoma.“These responses demonstrate that our proprietary SPEAR T-cell platform is clearly active and can overcome the challenges of treating a range of solid tumors with a T-cell therapy product,” CEO Adrian Rawcliffe commented.While only two of the responses were confirmed, the implications are significant. The efficacy of SPEAR T-cells in sarcoma has already been demonstrated, but some have been skeptical of the TCR/cell therapy approach in treating other forms of cancer based on a lack of responses among patients with more common solid tumors.As a result, the news was a pleasant surprise as investors had grown increasingly concerned about ADAP’s ability to address markets other than sarcomas.Weighing in, Cowen & Co. analyst Marc Frahm believes that thanks to the new data, the assumption that “sarcomas are uniquely susceptible to TCR therapy” should be reevaluated. Noting that the results were definitely unexpected, he argues that they highlight the potential of MAGE-A4 antigens.“It appears possible that the prior lack of responses may not have been a sign of complete insensitivity but rather a sign that the activation hurdle is merely a little higher outside of sarcoma. We are therefore hopeful that MAGE-A4’s utility may ultimately expand beyond subsets of sarcoma,” Frahm wrote in a note to clients.However, the four-star analyst tells investors that the key takeaway is ADP-A2AFP’s impressive performance. He stated, “The first hepatocellular carcinoma (HCC) patient treated at a dose of 5B cells within the Phase I trial of ADP-A2AFP has achieved a confirmed PR with 100% shrinkage of target lesions. Importantly, this patient was heavily pretreated as they had previously received treatment with a PD-1 inhibitor, sorafenib, and lenvatinib." As the candidate has already delivered a dosing response, Frahm thinks that “robust efficacy may be possible in HCC.”All of the above factors played into the analyst’s conclusion that substantial upside for ADAP shares is in sight. To this end, Frahm reiterated an Outperform rating without attaching an exact price target. (To watch Frahm’s track record, click here)With respect to other Wall Street analysts, only one other review of ADAP has been issued in the last three months. As that call was a Hold, the consensus rating lands at a Moderate Buy. However, it remains to be seen if the data will prompt other analysts to throw their opinions into the mix. (See Adaptimmune price targets and analyst ratings on TipRanks)To find good ideas for biotech stocks trading at fair value or better, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- Benzinga
The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 13.) Arvinas Inc (NASDAQ: ARVN ) Baxter International ...
- GlobeNewswire
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas"), through its wholly-owned subsidiary Universal Cells, Inc, and Adaptimmune Therapeutics plc (ADAP), a leader in cell therapy to treat cancer, announced that they have entered into a co-development and co-commercialization agreement to bring new stem-cell derived allogeneic T-cell therapies to people with cancer. Astellas and Adaptimmune will agree on up to three targets and co-develop T-cell therapy candidates directed to those targets.
- GlobeNewswire
Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 13, 2020 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, today announced the.
- GlobeNewswire
Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (ADAP), a leader in cell therapy to treat cancer, reported today, at the 38th JP Morgan Healthcare Conference, two confirmed Partial Responses (PRs) – one in a patient with liver cancer and one in a patient with melanoma. There are also two unconfirmed PRs – one in a patient with gastro‑esophageal junction cancer and one in a patient with head and neck cancer.
- Simply Wall St.
Adaptimmune Therapeutics (NASDAQ:ADAP) Will Have To Spend Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
- Insider Monkey
Is Adaptimmune Therapeutics plc (ADAP) Going To Burn These Hedge Funds ?
Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren't very good. However, our research shows this not to be the case. In fact, when it comes to their very top picks collectively, they show a strong ability […]
- American City Business Journals
Adaptimmune gets FDA designation to accelerate development of cancer therapy
The Food and Drug Administration has awarded a key designation to a therapy Adaptimmune is developing for a rare type of cancer. Adaptimmune's experimental T-cell therapy, called ADP-A2M4, targets synovial sarcoma, a cancer that occurs primarily in the extremities of the arms or legs. The FDA designated ADP-42M4 as a regenerative medicine advanced therapy.
- GlobeNewswire
Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADP‑A2M4 for the Treatment of Synovial Sarcoma
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Dec. 03, 2019 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that.
- Thomson Reuters StreetEvents
Edited Transcript of ADAP earnings conference call or presentation 6-Nov-19 1:00pm GMT
Full Year 2019 Adaptimmune Therapeutics PLC Earnings Call
- GlobeNewswire
Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial Sarcoma
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 16, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (ADAP), a leader in T-cell therapy to treat cancer, presented updated data from people with synovial sarcoma treated in the ongoing Phase 1 trial with ADP-A2M4. The oral presentation by Brian Van Tine, MD, PhD of Washington University School of Medicine in St. Louis, took place earlier today at the Connective Tissue Oncology Society (CTOS) annual meeting in Tokyo, Japan.
- GlobeNewswire
Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update
- Clinical responses with ADP-A2M4 in 7 out of 12 patients with synovial sarcoma, and clinical benefit in 11 out of 12 patients - - ADP-A2M4 granted Orphan Drug.
- GlobeNewswire
Adaptimmune to Report Third Quarter 2019 Financial Results and Business Update on Wednesday, November 6, 2019
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 01, 2019 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will report financial.
- Insider Monkey
Is Adaptimmune Therapeutics plc (ADAP) Is Burning These Hedge Funds
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
- Simply Wall St.
Do Directors Own Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares?
Every investor in Adaptimmune Therapeutics plc (NASDAQ:ADAP) should be aware of the most powerful shareholder groups...
- GlobeNewswire
Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune’s Cell Therapies
PHILADELPHIA and OXFORDSHIRE, United Kingdom and IRVINE, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (ADAP), a leader in T-cell therapy to treat cancer, and Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) ("Cryoport"), the world's leading temperature-controlled logistics solutions company dedicated to the life sciences industry, announce a 3-year agreement to ensure safe and fully monitored transport of Adaptimmune’s cell therapies. This agreement with Cryoport will contribute to this, alongside other solutions including investment in the latest systems and technology, digitization of the supply chain information, and improved communications with patients and healthcare professionals. “Control and monitoring are critical because a simple temperature variation can jeopardize these cells and, ultimately, the product we supply to patients.
- GlobeNewswire
Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 01, 2019 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, announces the.
- GlobeNewswire
Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 30, 2019 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented.
